On Thursday, Veracyte earned a positive adjustment to its Relative Strength (RS) Rating, from 80 to 90.
This exclusive rating from Investor's Business Daily measures price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
History shows that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves.
Here Are 3 Keys For Successful Stock Investing
While now is not an ideal time to invest, see if the stock is able to offer and clear an appropriate buy point.
Veracyte showed 71% earnings growth last quarter, while sales growth came in at 21%.
Veracyte holds the No. 2 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
